Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 4/20 | 0.37 |
| ▸ | ACR | P10323 | 4/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.39 |
| ▸ | KLK1 | P06870 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | C1R | P00736 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597132 | 0.96 | MAPT (0.41) | ACRTMPRSS15PRSS1MAPTTDP1 | |
| SCHEMBL7309964 | 0.84 | ACR (0.42) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL1645313 | 0.79 | KMT2A (0.44) | ACRTMPRSS15PRSS1MAPTTDP1 | |
| SCHEMBL5177919 | 0.79 | PRSS1 (0.37) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL1399025 | 0.75 | ACR (0.41) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL5634875 | 0.75 | MAPT (0.46) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL1399026 | 0.70 | KMT2A (0.43) | ACRTMPRSS15PRSS1MAPTTDP1 | |
| SCHEMBL11305079 | 0.70 | ALDH1A1 (0.47) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL7315833 | 0.67 | PRSS1 (0.42) | ACRTMPRSS15PRSS1KLK1MAPT | |
| SCHEMBL28467251 | 0.65 | PRSS1 (0.61) | ACRTMPRSS15PRSS1KLK1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696960-B1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | AMYLIN PHARMACEUTICALS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1965828-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | Nastech Pharmaceutical Company Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1539220-A4 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | NASTECH PHARM CO (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007146448-A1 | PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007065156-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006007412-A9 | PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS | NASTECH PHARM CO (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060210614-A1 | Mucosal delivery-enhancing agent selected from a solubilization agent; a charge-modifying agent; a pH control agent; a degradative enzyme inhibitor; a mucolytic/mucus clearing agent; increased bioavailability of exendins peptide when administered intranasally to a mammal; antidiabetic/antiobesity agent | NASTECH PHARMACEUTICAL COMPANY INC. | 2006-09-21 | — | — | US | disclosed |
| US-20060069021-A1 | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs | NASTECH PHARMACEUTICAL COMPANY INC. | 2006-03-30 | — | — | US | disclosed |
| EP-1539220-A2 | COMPOSITIONS AND METHOD FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | Nastech Pharmaceutical Company Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004002404-A2 | COMPOSITIONS AND METHOD FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2004-01-08 | — | — | WO | disclosed |